Important catalysts expected to occur during the fourth quarter of 2019 include US approval decisions for brolucizumab in wet age- related macular degeneration (AMD) and for a long- acting cabotegravir and rilpivirine combination, CARLA, to treat HIV-1 infection, as well as top- line results from a phase III study of SAGE-217 in major depressive disorder (MDD). Para acessar a publicação na íntegra clique aqui Fonte: 738 | OCTOBER 2019 | volume 18 BiObusinEss BRiEfs www.nature.com/nrd…